Serum Pharmacochemistry and Network Pharmacology Reveal Active Compoun

Introduction

Radiotherapy is a cornerstone in the management of various cancers, but its collateral damage to healthy lung tissue can result in long-term complications such as radiation-induced pulmonary fibrosis (RIPF).¹ RIPF is characterized by the progressive and irreversible scarring of lung tissue, leading to impaired lung function and reduced quality of life for affected patients. The underlying pathogenesis of RIPF involves a complex interplay of inflammatory responses, oxidative stress, fibroblast activation, and excessive extracellular matrix (ECM) deposition.² Despite advancements in radiation therapy techniques, the incidence of RIPF remains concerning, especially after radiation therapy for thoracic malignancies.³ The lack of effective interventions to prevent or ameliorate RIPF underscores the urgent need…